<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="477">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636320</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2020/22</org_study_id>
    <nct_id>NCT04636320</nct_id>
  </id_info>
  <brief_title>Prevalence of Myocardial Scars on CMR After COVID-19 Infection</brief_title>
  <acronym>COVID-CMR</acronym>
  <official_title>Prevalence of Silent Myocardial Scars on Cardiac Magnetic Resonance Following COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grant Agreement ERC nÂ°715093</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bordeaux - mission UB-C19</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the prevalence and arrhythmogenic role of occult&#xD;
      myocardial scars on Cardiac Magnetic Resonance (CMR) in a population of patients with history&#xD;
      of laboratory-proven symptomatic COVID-19 infection managed without hospitalization, as&#xD;
      compared to a population of age- and sex-matched healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple large series conducted in hospitalized patients have reported high rates of&#xD;
      myocardial injuries in the acute stage of COVID-19 infection. These findings have raised&#xD;
      concerns regarding potential long term consequences of the pandemic on cardiovascular&#xD;
      diseases (heart failure and sudden cardiac deaths due to scar-related arrhythmias). However,&#xD;
      the prevalence of silent myocardial injuries in the general population who presented a&#xD;
      COVID-19 infection managed without hospitalization are unknown. In addition, the propensity&#xD;
      of these scars to generate arrhythmias have not been thoroughly studied. COVID CMR will&#xD;
      include 120 patients with history of laboratory-proven symptomatic COVID-19 infection managed&#xD;
      without hospitalization and 120 age- and sex-matched controls. At day 1, all subjects will&#xD;
      undergo a 12-lead electrocardiogram, a contrast-enhanced CMR study including advanced methods&#xD;
      to detect silent myocardial scars, and a blood sample to look for markers of inflammation and&#xD;
      cardiac injury, and to assess the COVID-19 serological status at the time of the CMR study.&#xD;
      The prevalence of myocardial scars on CMR will be compared between the 2 groups. In a second&#xD;
      visit at 3 months, patients showing myocardial scar on CMR will be matched to healthy&#xD;
      volunteers showing no such scars, and these 2 population subsets will undergo exercise&#xD;
      electrocardiogram (ECG) and 24 hour Holter ECG to characterize the arrhythmogenic role of&#xD;
      silent myocardial scars.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2020</start_date>
  <completion_date type="Anticipated">April 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-centre case-control study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of myocardial scars</measure>
    <time_frame>Day 0</time_frame>
    <description>Expressed in percentage of participant, as assessed on late gadolinium-enhanced magnetic resonance acquired at high resolution using a free breathing 3D method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMR feature : Location and size of myocardial scars</measure>
    <time_frame>Day 0</time_frame>
    <description>Measured in mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR feature : native T1 and T2 values</measure>
    <time_frame>Day 0</time_frame>
    <description>Measured in milliseconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR feature : extracellular volume fraction</measure>
    <time_frame>Day 0</time_frame>
    <description>Measured in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR feature : ventricular volumes</measure>
    <time_frame>Day 0</time_frame>
    <description>Measured in mL/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR feature : ejection fraction</measure>
    <time_frame>Day 0</time_frame>
    <description>Measured in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR feature : myocardial strain</measure>
    <time_frame>Day 0</time_frame>
    <description>Measured in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG features</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>Repolarization abnormalities, T wave inversion, ST segment abnormalities, QRS fractionation, atrial arrhythmias, premature ventricular beats or ventricular tachycardia.These will be assessed at the time of CMR study on a resting 12-lead ECG recording and on exercise 12-lead ECG and 24-hour Holter ECG recordings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological feature : positivity of COVID-19 serology</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>Rate of seropositivity in asymptomatic volunteers and rate of seronegativity in patients with a history of symptomatic episodes.&#xD;
Measured in percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological feature : troponin level</measure>
    <time_frame>Day 0</time_frame>
    <description>Measured in fg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological feature : inflammatory markers level</measure>
    <time_frame>Day 0</time_frame>
    <description>Markers of inflammation and fibrosis will be sought. The Th1/Th2/activation/inflammation/apoptosis markers will be measured in the sera by a Luminex test allowing the detection of 48 analytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic profile research</measure>
    <time_frame>Day 0</time_frame>
    <description>Identified by sequencing genetic variants that could have an impact on the occurrence of a severe form in individuals infected with COVID-19</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>COVID-19</condition>
  <condition>Virus Disease</condition>
  <arm_group>
    <arm_group_label>Patient group COVID-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 patients with history of laboratory-proven symptomatic COVID-19 infection managed without hospitalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteer group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>120 healthy volunteers. Age- and sex-matched controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Contrast-enhanced CMR</intervention_name>
    <description>Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.</description>
    <arm_group_label>Healthy volunteer group</arm_group_label>
    <arm_group_label>Patient group COVID-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Exercise test ECG</intervention_name>
    <description>A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.&#xD;
Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.</description>
    <arm_group_label>Healthy volunteer group</arm_group_label>
    <arm_group_label>Patient group COVID-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.&#xD;
An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers.</description>
    <arm_group_label>Healthy volunteer group</arm_group_label>
    <arm_group_label>Patient group COVID-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Resting 12 lead ECG</intervention_name>
    <description>A resting 12 lead ECG will be performed at Day 0 visit.</description>
    <arm_group_label>Healthy volunteer group</arm_group_label>
    <arm_group_label>Patient group COVID-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>24 hour Holter ECG</intervention_name>
    <description>A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.</description>
    <arm_group_label>Healthy volunteer group</arm_group_label>
    <arm_group_label>Patient group COVID-19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman â¥ 18 years old&#xD;
&#xD;
          -  Affiliated to a health insurance program&#xD;
&#xD;
          -  Providing free, informed, written and signed consent to participate (at the latest on&#xD;
             the day of inclusion and before any research procedure is initiated)&#xD;
&#xD;
          -  Effective contraception if women in the age to procreate&#xD;
&#xD;
          -  In the patient group : history of COVID-19 infection with either a positive Reverse&#xD;
             Transcriptase Polymerase Chain Reaction (RT-PCR) test on nasopharyngeal swab or a&#xD;
             positive COVID-19 serology in the acute stage. Presence of all following symptoms in&#xD;
             the acute stage: fever&gt;38Â°C, asthenia, arthromyalgia, associated with at least 2 of&#xD;
             the following: coughing and/or spitting, dyspnea and/or chest discomfort, anosmia&#xD;
             and/or ageusia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 years old&#xD;
&#xD;
          -  History of cardiac disease or acute coronary syndrome associated with troponin rise&#xD;
&#xD;
          -  History of allergic reaction to gadolinium-based contrast agents&#xD;
&#xD;
          -  History of severe renal failure&#xD;
&#xD;
          -  Presence of a pacemaker, implantable defibrillator, intra-orbital metallic material,&#xD;
             intra-cranial surgical clip, valve prosthesis Star-Edwards pre 6000, neurostimulator&#xD;
             or implantable insulin pump&#xD;
&#xD;
          -  Claustrophobia or inability to lay on the back for 50 min&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Inability to express informed consent&#xD;
&#xD;
          -  Person deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Person under legal protection&#xD;
&#xD;
          -  In the healthy volunteer group:&#xD;
&#xD;
               -  Symptoms suggestive of COVID-19 infection over the epidemic period (after&#xD;
                  February 1st 2020)&#xD;
&#xD;
               -  Person not willing to be informed of potential incidental CMR findings&#xD;
&#xD;
          -  In the patient group:&#xD;
&#xD;
               -  Hospitalization for infectious syndrome suggestive of COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert COCHET, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hubert COCHET, MD-PhD</last_name>
    <phone>(0)5.57.65.65.42</phone>
    <phone_ext>+33</phone_ext>
    <email>hubert.cochet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie COTTIGNIES</last_name>
    <phone>(0)5.57.62.31.96</phone>
    <phone_ext>+33</phone_ext>
    <email>nathalie.cottignies@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert COCHET, MD-PhD</last_name>
      <phone>(0)5.57.65.65.42</phone>
      <phone_ext>+33</phone_ext>
      <email>hubert.cochet@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie COTTIGNIES</last_name>
      <phone>(0)5.57.62.31.96</phone>
      <phone_ext>+33</phone_ext>
      <email>nathalie.cottignies@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Hubert COCHET, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre JAÃ¯S, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Scar</keyword>
  <keyword>Cardiac Magnetic Resonance</keyword>
  <keyword>Arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

